ANI ‘On The Cusp Of A Transformation’ Following Cortrophin Launch

Company Expects Up To $40m From The Product In 2022

 
• By Chloe Kent

ANI Pharmaceuticals appeared confident about its Cortrophin gel launch and integration of Novitium Pharma as it rounded up its Q1 results, but net losses have dampened the company’s share value.

Close up of ANI sign at their Canadian head office in Oakville
ANI's share price took a hit following losses related to commercial expenses. • Source: Shutterstock

More from Earnings

More from Business